Lymphocytic Leukemia

Lymphocytic leukemia is a type of cancer that starts in the blood cells, specifically the lymphocytes. These are a type of white blood cell that helps fight infection. In this disease, the lymphocytes grow and divide uncontrollably, crowding out healthy blood cells and making the person very sick. It's often called lymphocytic leukemia because it affects the lymphocytes.

Condition

What people with Lymphocytic Leukemia report

Every report comes from a Lived member, sent anonymously.

Have you had Chemotherapy infusion for Lymphocytic Leukemia?

NameHow it went

About Lymphocytic Leukemia

What It Is

Lymphocytic leukemia, also called lymphoid leukemia, is a group of blood cancers that begin in the bone marrow, the soft tissue inside bones where blood cells are made. In these leukemias the marrow produces too many abnormal lymphocytes, a type of white blood cell that normally helps fight infection. The abnormal cells do not protect against infection well, and as they build up they crowd out healthy blood cells. That can lead to anemia (too few red blood cells), easy bruising or bleeding (from too few platelets, the cells that help blood clot), and frequent infections. The name covers two main diseases that behave very differently. Acute lymphoblastic leukemia (ALL) grows quickly and needs treatment soon after diagnosis. It is the most common cancer in children, appearing most often between ages 1 and 4, although adults can develop it too. Chronic lymphocytic leukemia (CLL) usually progresses slowly, over years. It is one of the most common leukemias in adults, is typically diagnosed in middle age or later and is rare in children. Because the two differ so much, knowing the specific type matters far more than the umbrella name. Rarer forms, such as hairy cell leukemia, have their own patterns and treatments.

Causes & Risk Factors

Both ALL and CLL arise from changes in the genetic material (DNA) of developing blood cells. In most people, what set off those changes is unknown, and nothing the person did caused them. A risk factor raises the chance of developing leukemia but does not decide it: many people with risk factors never get leukemia, and many who do had none. For ALL, known risk factors include earlier chemotherapy or radiation therapy, exposure to high levels of radiation, and certain inherited conditions, most notably Down syndrome. In adults, ALL is more common in men and in people over 70. For CLL, the main risk factor is age; most people are over 50 at diagnosis. A family history of CLL or other blood and bone marrow cancers raises risk, and CLL is more common in white people than in other groups. Exposure to certain chemicals, including Agent Orange used during the Vietnam War, has also been linked to CLL.

How It's Diagnosed

Diagnosis usually starts with a complete blood count (CBC), a routine blood test that counts red cells, white cells and platelets and shows which kinds of white cells are present. A clinician also looks at a blood sample under a microscope and checks for swollen lymph nodes, liver or spleen. CLL is often found this way in someone with no symptoms, when a routine test shows a high lymphocyte count. A test called flow cytometry then reads the markers on the cells' surface to confirm that they come from a single abnormal family of B lymphocytes. CLL is generally diagnosed when these abnormal B cells number at least 5,000 per microliter of blood. A smaller abnormal population, with no enlarged lymph nodes or spleen, is called monoclonal B-cell lymphocytosis. It is a precursor that is followed with periodic blood tests, and only a small share of people with it go on to need treatment for CLL. Genetic tests on CLL cells, such as checking for changes in a gene called TP53, help predict how the leukemia will behave and which treatments are likely to work. ALL is confirmed with a bone marrow aspiration and biopsy: after the skin is numbed, a needle removes a small sample of marrow and bone, usually from the hipbone. The sample shows how much of the marrow has been taken over by immature leukemia cells called blasts and whether they arose from B or T lymphocytes. Chromosome and gene tests look for changes that steer treatment, such as the Philadelphia chromosome, a swap of material between two chromosomes that creates an abnormal growth signal. A lumbar puncture (spinal tap) checks the fluid around the brain and spinal cord, because ALL can spread there.

Treatment Options

Treatment depends first on which type of leukemia someone has. For ALL, treatment starts promptly and comes in phases. The first phase, induction, uses combinations of chemotherapy drugs to clear leukemia cells from the blood and marrow and bring about remission, meaning normal blood counts and 5 percent or fewer blasts in the marrow. Later phases aim to destroy leftover cells that could cause a relapse: consolidation, and a long, lower-intensity maintenance phase, especially in children, much of it taken at home. Childhood treatment typically lasts 2 to 3 years in total. Because standard chemotherapy does not reach the brain and spinal cord well, treatment directed there, usually chemotherapy injected into the spinal fluid, is usually part of each phase. ALL treatment is also matched to age and the leukemia's genetic features. Philadelphia chromosome-positive ALL adds a targeted pill called a tyrosine kinase inhibitor, such as imatinib (Gleevec). Blinatumomab (Blincyto) is an infused immunotherapy that links the person's own T cells to leukemia cells; it is used for some people in remission who still have small traces of leukemia, as part of consolidation for some, and for leukemia that returns. For high-risk or relapsed disease, options include a stem cell transplant from a donor and chimeric antigen receptor (CAR) T-cell therapy, in which a person's own immune cells are re-engineered in a laboratory to attack the leukemia. Transplant and CAR T-cell therapy can bring lasting remission for some people whose leukemia is high risk or has returned, but they carry real short-term risks, especially serious infection, and some have long-term effects. CLL is approached very differently. Many people with early CLL and no symptoms are not treated right away. Instead they have regular checkups and blood counts, an approach called watchful waiting or active monitoring. Studies have found that starting treatment early in this situation does not help people live longer, while waiting spares them side effects. Treatment usually begins when CLL causes symptoms such as persistent fevers, night sweats or weight loss, when lymph nodes or the spleen become large or uncomfortable, or when red blood cell or platelet counts fall. Most CLL treatment today uses targeted drugs rather than traditional chemotherapy. Bruton tyrosine kinase (BTK) inhibitors, such as ibrutinib (Imbruvica), acalabrutinib (Calquence) and zanubrutinib (Brukinsa), are pills that block a signal CLL cells depend on; they are usually taken every day for as long as they keep working and are tolerated. Venetoclax (Venclexta) is a pill that blocks a protein CLL cells use to avoid dying. It is often given with the infused antibody obinutuzumab for a fixed course of about a year. It starts at a low dose that is raised over five weeks with blood tests, because killing many leukemia cells at once can cause tumor lysis syndrome, a release of cell contents that can damage the kidneys. Choosing between ongoing and fixed-length treatment depends on the leukemia's genetic features, other health conditions and medicines, and personal preference. For most people, treatment controls CLL for long periods but does not cure it; a donor stem cell transplant is reserved for selected people whose disease keeps returning.

What to Expect

ALL treatment is intensive, especially in the first months. It often involves hospital stays, a central line (a long-term IV catheter) for medicines and blood draws, frequent clinic visits, and stretches when blood counts are very low and infection risk is high. Fatigue, hair loss, nausea and time away from school or work are common during the intense phases. Outcomes for children have improved greatly: with current treatment, more than 90 percent of children and teens are alive five years after diagnosis, and most become long-term survivors. Across all ages in the United States, about 73 percent of people with ALL are alive five years after diagnosis, and the outlook for an adult depends strongly on age and on the leukemia's genetic features. Survivors need long-term follow-up, because some treatments can affect the heart, bones, liver and fertility and can raise the risk of a second cancer years later. CLL is usually a long-term condition rather than a short crisis. Many people stay stable for long periods, and some go years before needing any treatment. In the United States, about 90 percent of people with CLL are alive five years after diagnosis, although individual outlook varies with the stage and genetic features of the disease. Waiting without treatment can feel unsettling, but regular visits that track blood counts, lymph nodes and symptoms are an active form of care. Survival statistics describe large groups and cannot predict what will happen to any one person. CLL weakens the immune system, including its ability to make antibodies, so bacterial and viral infections, such as shingles, are more frequent and can be more serious, even before any treatment. Infection prevention, including planning vaccines with the care team, is part of everyday life with CLL.

When to Seek Help

See a clinician if you have tiredness that does not improve with rest, painless swollen lymph nodes in the neck, armpit or groin, or a routine blood test showing an abnormal white cell count. Seek a prompt appointment, within days, for easy bruising, nosebleeds or bleeding gums, bone pain, paleness or repeated infections, particularly in a child, because ALL can worsen over days to weeks. A child with unexplained tiny red or purple dots on the skin (petechiae), or petechiae with a fever, needs to be seen by a doctor the same day. If you are living with CLL, contact your hematologist about new fevers without an obvious infection, soaking night sweats, weight loss you did not intend, or lymph nodes that grow quickly. These can mean the leukemia is progressing or, less commonly, changing into a faster-growing lymphoma. New bruising, yellowing skin or dark urine also needs a call, because CLL can lead the immune system to destroy red blood cells or platelets. During treatment, a fever of 100.5 F (38 C) or higher, shaking chills, or redness or swelling where a central line enters the skin needs a call to the cancer care team right away, at any hour, because infections when white cell counts are low can become life threatening quickly. Follow the fever plan your team gives you, and check with them before taking acetaminophen or ibuprofen, since these can hide a fever.

Questions to Ask Your Doctor

  1. 1.Which type of lymphocytic leukemia do I have, and what do the genetic test results say about how it is likely to behave?
  2. 2.If I have CLL, what changes in my symptoms or blood counts would mean it is time to start treatment?
  3. 3.What is the goal of the treatment you recommend, how long will it last, and how does it compare with the alternatives?
  4. 4.What should I do if I get a fever or other sign of infection, and which vaccines should I have or avoid?
  5. 5.What long-term follow-up will I or my child need once treatment ends?

Last reviewed • Oct 2026

Educational content, not medical advice.